Effervescent tablets: a safe and practical delivery system for drug administration

Efervesans, bir sıvı içinde oluflan kimyasal reaksiyon sonucu, çözünme ve gaz kabarcıklarının oluflması olarak tarif edilmektedir. Tıbbi kullanımda efervesan tabletler, verilen ilacın hızlı emilimini sa¤lamaya yönelik bir özellik taflımaktadır. Verilen ilaç, e¤er su içinde yeterli dozda ve kolayca çözünürse daha hızlı ve etkin flekilde emilim sa¤lanacaktır. Kö- pürme reaksiyonu için genellikle sitrik, malik, tartarik, adipik veya fumarik asitler kullanılmaktadır. En sık tercih edilen, ürüne hafif bir limon aroması da veren sitrik asittir. Tartarik, adipik ve fumarik asitler, suda çözünürlükleri daha düflük oldu¤u için daha az miktarlarda kullanılırlar. Uygun ilaç dozu alımının sa¤lanması, ilaca uyumun kolaylafltı- rılması, hızlı ve daha iyi emilim, hastanın sıvı alımının artırılması ve bü- yük tabletlerin yutulma zorlu¤unun ortadan kaldırılması için efervesan tabletler kullanılmaktadır. Bu derlemede, teknolojik açıdan efervesan tabletler de¤erlendirilmifl, avantaj ve dezavantajları tanımlanmıfltır.

Efervesan tabletler: İlaç kullanımı için güvenli vepratik bir uygulama sistemi

Effervescence is defined as the evolution of gas bubbles from a liquid as aresult of a chemical reaction. For medicinal use, effervescent tablets havespecific characteristics that allow rapid adsorption of the intended drug.In this manner, a medication can be absorbed easily and effectively if itdissolves easily in water and is present at a sufficient dose. Common acidsutilized for effervescent reactions are citric, malic, tartaric, adipic andfumaric acids. Citric acid is most commonly used for this application,which also adds a citrus-like taste to the products. Tartaric, adipic andfumaric acids are usually used in small amounts, due to their low watersolubility. Effervescent tablets are used to simplify the handling of doses,provide optimal compatibility, promote superior and rapid absorption,increase a patient's liquid intake and circumvent the difficulty of swallowing large pills. This review defines effervescent tablets in terms of thetechnology and describes the advantages and disadvantages.

___

  • 1. Rajlakshmi G, Vamsi C, Balchandar R, Damodharan N. Formulation and evaluation of effervescent tablets of diclofenac potassium. International Journal of Pharmaceutical and Biomedical Research 2011;2;237-43.
  • 2. Mohrle R. Effervescent tablets. In: Liberman HA, Lachman L. Schwartz JB, editors. pharmaceutical dosage form-tablets. Vol. I. First Indian reprint. New York, NY: Marcel Dekker Inc.; 2005. p. 285-92.
  • 3. Stahl H. Effervescent dosage manufacturing. Pharmaceutical Technology Europe 2003;15:25-8.
  • 4. Swarbrick J, Boylon JC. Encyclopedia of pharmaceutical technology. Vol. 1. New York, NY: Marcel Dekker Inc.; 2002. p. 1037-49. 5. Tekade BW, Jadhao UT, Thakre VM, Bhortake LR.
  • Formulation and evaluation of diclofenac sodium effervescent tablet. Innovations in Pharmaceuticals and Pharmacotherapy 2014;2:350-8.
  • 6. Prabhakar CH, Krishna KB. A review on effervescent tablet. International Journal of Pharmacy and Technology 2011;3:704-12. 7. Sweetman SC. Martindle: the complete drug reference. 35th ed. London: Pharmaceutical Press; 2007.
  • 8. Aslani A, Fattahi F. Formulation, characterization and physicochemical evaluation of potassium citrate effervescent tablets. Adv Pharm Bull 2013;3:217-25.
  • 9. Pham JH. Understanding effervescent tableting technology [cited 2015 Nov 29]. Available from:.http://www.naturalproductsinsider.com/articles/2008/05/understanding-effervescenttableting-technology.aspx
  • 10. Tian XF, Bian BL. Development of effervescent tablet of Chinese traditional medicine and its technology study. [Article in Chinese] Zhongguo Zhong Yao Za Zhi 2004;29:624-7.
  • 11. Lachman L, Liberman HA, Kanig JL. The theory and practice of industrial pharmacy. 3rd ed. Philadelphia, PA: Lea and Febiger; 1986. 12. Allen LV, Popovich NG, Ansel HC. Ansel's pharmaceutical dosage forms and drug delivery systems. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010.
  • 13. Swarbrick J, Boylan JC. Encyclopedia of pharmaceutical technology. New York, NY: Marcel Dekker; 2002.
  • 14. Altomare E, Vendemiale G, Benvenuti C, Andreatta P. Bioavailability of a new effervescent tablet of ibuprofen in healthy volunteers. Eur J Clin Pharmacol 1997;52:505-6.
  • 15. Monrle R. Effervescent tablet. In: Liberman HA, Lachman I, Schwartz J, editors. Pharmaceutical dosage form: tablets. 2nd ed. New York, NY: Marcel Dekker Inc; 1980.
  • 16. Callahan JC, Cleary GW, Elefant M, Kaplan G, Kensler T, Nash RA. Equilibrium moisture content of pharmaceutical excipients. Drug Dev Ind Pharm 1982;8:355-69.
  • 17. Saleh SI, Boymond C, Stamm A. Preparation of direct compressible effervescent components: spray-dried sodium bicarbonate. Int J Pharm 1988;45:19-26.
  • 18. Tekin A, Tekgul S, Atsu N, Bakkaloglu M, Kendi S. Oral potassium citrate treatment for idiopathic hypocitruria in children with calcium urolithiasis. J Urol 2002;168:2572-4.
  • 19. Pak CY, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 1986;30:422-8.
  • 20. Pak CY, Peterson RD, Poindexter J. Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis. J Urol 2002; 168:31-4.
  • 21. McEvoy GK. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists; 2005.
  • 22. Møller PL, Nørholt SE, Ganry HE, et al. Time to onset of analgesia and analgesic efficacy of effervescent acetaminophen 1000 mg compared to tablet acetaminophen 1000 mg in postoperative dental pain: a single-dose, double-blind, randomised, placebocontrolled study. J Clin Pharmacol 2000;4:370-8.
  • 23. Effervescent technology primer [cited 2015 Nov 29]. Available from: http://www.lotioncrafter.com/pdf/Effervescent_Technology_ Primer.pdf
  • 24. Effervescent benefits [cited 2015 Nov 29]. Available from: http://www.amerilabtech.com/expertise/effervescent-benefits/ 25. Palanisamy P, Abhishekh R, Yoganand Kumar D. Formulation and evaluation of effervescent tablets of aceclofenac. International Research Journal of Pharmacy 2011;2:185-90.
  • 26. Srinath KR, Pooja Chowdary CP, Palanisamy P, et al. Formulation and evaluation of effervescent tablets of paracetamol. International Journal of Pharmaceutical Research and Development 2011;3:76- 104.
  • 27. Lee RE. Effervescent tablets 2010 [cited 2015 Nov 29]. Available from: http://www.amerilabtech.com/wp-content/uploads/Effervescent TabletsKeyFacts.pdf
  • 28. Wadhwani AR, Prabhu NB, Nadkarni MA, Amin PD. Consumer friendly mucolytic formulations. Indian J Pharm Sci 2004;7:506-7.
  • 29. Bandeline FJ. Granulation. In: Liberman HA, Lachman L, Schwartz JB, editors. Pharmaceutical dosage forms: tablets. New York, NY: Marcel Dekker Inc; 1989. p. 287-92.
  • 30. Bhusan SY, Sambhaji SP, Anant RP, Kakasaheb RM. New drug delivery system for elderly. Indian Drugs 2000;37:312-8.
  • 31. Aslani A, Jahangiri H. Formulation, characterization and physicochemical evaluation of ranitidine effervescent tablets. Adv Pharm Bull 2013;3:315-22.
ENT Updates-Cover
  • ISSN: 2149-7109
  • Başlangıç: 2015
  • Yayıncı: Prof.Dr.Murat Demir
Sayıdaki Diğer Makaleler

İleri evre Iarenks kanserinde bilgisayarlı tomografideki potansiyel tuzaklar

Hale ASLAN, ERCAN PINAR, Sedat ÖZTÜRKCAN, İbrahim ALADAĞ, Nezahat Karaca ERDOĞAN, Demet ETİT, Bilge Demirkol TUNA, Abdulkadir İMRE, YÜKSEL OLGUN, Düzgün ATEŞ

Baş ve boyun kanserli hastalarda gizli lenf nodu metastazı insidansı

Onur KIRAT, Mehmet Özgür PINARBAflLI, Melek Kezban GÜRBÜZ, Ercan KAYA, Erkan ÖZÜDOĞRU

Sitokin geni polimorfizmleri ve Türk pediyatrik koklear implant hastalar>ndaki ekspresyonu

ELİF BAYSAL, SİBEL OĞUZKAN BALCI, Fatih ÇELENK, Merve KAHRAMAN, Murat DENİZ, ORHAN TUNÇ, Cengiz DURUCU, LÜTFİ SEMİH MUMBUÇ, MUZAFFER KANLIKAMA, SACİDE PEHLİVAN

Attik kolesteatom fonksiyonel cerrahisinin uzun dönem sonuçları

Erdem Atalay ÇETİNKAYA, İBRAHİM ÇUKUROVA, Levent OLGUN, Raci KABAKÇI

Bir üçüncü basamak hastanesindeki kronik dakriyosistit hastalarının kültür sonuçlarının klinik ve mikrobiyolojik değerlendirmesi

Murat GÜMÜŞSOY, İBRAHİM ÇUKUROVA, Gülfem ECE, Erdem Atalay ÇETİNKAYA

Obstrüktif uyku apnesinde oksijen satürasyonunun %90-95 altında kaldığı durumlarda uyku süresi ile klinik ve laboratuvar bulguları arasındaki ilişki

SUAT AVCI, AYNUR YILMAZ AVCI, Berna Devrim YAĞBASAN, Hüseyin GÜNİZİ

Effervescent tablets: a safe and practical delivery system for drug administration

Kağan İPÇİ, Tuğba ÖKTEMER, Leman BİRDANE, Niyazi ALTINTOPRAK, Nuray Bayar MULUK, Desiderio PASSALI, Andrey LOPATİN, Luisa BELLUSSI, Ranko MLADİNA, Ruby PAWANKAR, CEMAL CİNGİ

Yüksekten düflmenin neden oldu¤u trakea rüptürü

Burcu HIZARCI, CEM ERDOĞAN, HÜSEYİN ÖZ

İris rengi ve retina pigment epitel melanininin alerjik rinite olan etkisi

FEVZİ SEFA DEREKÖY, Fethullah KENAR, GÜLİZ FATMA YAVAŞ, Tuncay KÜSBECİ, Faruk ÖZTÜRK, Abdullah AYÇİÇEK

Retraction: Yurttafl V et al. Prognostic factors for graft success in tympanoplasty with mastoidectomy. ENT Updates 2015;5:72-75

Veysel YURTTAŞ, AHMET URAL, Ahmet KUTLUHAN, Kazım BOZDEMİR